PLYXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Polaryx Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$1.92+0.04 (+2.13%)
Close on Oct 19, 2026
- Market cap
- $92.69M
- P/E (TTM)
- –
- Dividend yield
- –
Polaryx Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Polaryx Therapeutics | Industry median |
|---|---|---|
| Market Cap | $95.70M | $166.30M |
| Enterprise Value | $84.16M | $88.19M |
| PB Ratio | 8.75 | 2.03 |
| P/TBV Ratio | 8.75 | 2.29 |
Income (trailing twelve months)
| Measure | Polaryx Therapeutics | Industry median |
|---|---|---|
| Operating Income | -$7.82M | -$21.40M |
| Pretax Income | -$8.99M | -$14.34M |
| Net Income | -$8.99M | -$22.46M |
| EBITDA | -$7.82M | -$16.91M |
| EPS (Diluted) | -$0.20 | -$0.83 |
Returns
| Measure | Polaryx Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -126.7% | -53.2% |
| Return on Assets (ROA) | -76.1% | -40.9% |
| Return on Invested Capital (ROIC) | -467.5% | -32.4% |
| Return on Capital Employed (ROCE) | -71.5% | -38.1% |
Balance sheet
| Measure | Polaryx Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $11.54M | $61.43M |
| Net Cash (Debt) | $11.54M | $15.35M |
| Net Cash Per Share | $0.23 | $0.66 |
| Equity (Book Value) | $10.94M | $49.09M |
| Book Value Per Share | $0.22 | $1.37 |
| Tangible Book Value | $10.94M | $23.52M |
| Working Capital | $10.94M | $76.81M |
Financial position
| Measure | Polaryx Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 13.53 | 3.34 |
| Quick Ratio | 13.22 | 2.44 |
Cash flow (trailing twelve months)
| Measure | Polaryx Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$3.94M | -$12.35M |
Efficiency
| Measure | Polaryx Therapeutics | Industry median |
|---|---|---|
| Profits Per Employee | -$816.82K | -$703.34K |
| Employee Count | 11 | 74 |
Dividends and yields
| Measure | Polaryx Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -9.39% | -23.3% |
| Buyback Yield | -4.69% | -0.59% |
| Shareholder Yield | -4.69% | 0.00% |
Shares
| Measure | Polaryx Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 49,846,000 | 58,127,000 |
| Shares Change (YoY) | 32.8% | 10.9% |
| Shares Change (QoQ) | 5.29% | 0.54% |
| Float | 23,362,400 | 49,136,700 |
| Shares Held by Insiders | 53.1% | 11.6% |
| Shares Held by Institutions | 4.40% | 59.4% |
Scores
| Measure | Polaryx Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | 52.43 | -0.22 |
| Piotroski F-Score | 3 | 4 |
Calculated by StockData from Polaryx Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.